Prophylactic HPV vaccination: current status

Henry C Kitchener

in Vaccines for the Prevention of Cervical Cancer

Published on behalf of Oxford University Press

ISBN: 9780199543458
Published online May 2011 | e-ISBN: 9780199607181 | DOI:

Series: Oxford Oncology Library

Prophylactic HPV vaccination: current status

Show Summary Details


• Prophylactic human papilloma virus (HPV) vaccines have been developed against types 16 and 18, based on virus-like particles (VLPs) and which induce high titres of neutralizing antibodies, could potentially prevent 70% of cancers worldwide. • These vaccines are more than 90% effective at preventing type 16/18 associated CIN, although overall efficacy against all type CIN2/3 in all vaccine recipients, irrespective of current infection is considerably less. • There is evidence that the bivalent vaccine provides significant cross protection against CIN2+ associated with types 31, 33 and 45 and the quadrivalent vaccine against CIN 2+ associated with type 31 . • The quadrivalent vaccine has shown efficacy against type 16/18 related CIN2+ in women aged 24-45 who do not have 16/18 infection. • The optimal age group to vaccinate is pre-adolescent girls. • The possible need for booster vaccination to maintain pro-tection can only be determined by further follow-up data.

Chapter.  5522 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.